Anti-IL-23α (Tildrakizumab), Humanized Antibody

Anti-IL-23α (Tildrakizumab), Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a humanized IgG1 monoclonal antibody that specifically targets the p19 subunit of IL-23 and thereby inhibits the interaction with the IL-23 receptor. IL-23 is a cytokine that plays an important role in mediating inflammatory and immune responses. Binding of the antibody to Il-23 blocks the release of pro-inflammatory cytokines and chemokines associated with psoriasis. The original drug received approval from the FDA in 2018 to treat patients with moderate-to-severe plaque psoriasis who are candidates for systemic and phototherapy

Immunogen Sequence:Human IL-23α

Target Alternative Name:MK-3222, SCH 900222, P19, SGRF, IL-23, IL23A, IL23P19

Species Reactivities:Human

Tag Line:The biosimilar is a humanized monoclonal antibody that specifically targets IL-23 p19 subunit and inhibits the release of cytokines and chemokines involved in mediating inflammation in psoriasis

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.